{"id":397746,"date":"2020-12-10T16:04:14","date_gmt":"2020-12-10T21:04:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397746"},"modified":"2020-12-10T16:04:14","modified_gmt":"2020-12-10T21:04:14","slug":"opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/","title":{"rendered":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing"},"content":{"rendered":"
\n

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (\u201cAgreement\u201d) with a syndicate of Pontifax Medison Finance (\u201cPontifax\u201d), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe\u2019s leading growth debt firm.<\/p>\n

Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (\u201cFDA\u201d) at the end of 2021.<\/p>\n

Under the Agreement, Opiant will be able to draw up to $50 million in three tranches. The first tranche of\u00a0$20 million\u00a0was funded at closing on December 10, 2020; a second tranche of\u00a0$10 million will be available upon submission of a New Drug Application to the FDA; and a third tranche of $20 million will be funded upon FDA approval of an opioid overdose product. Each tranche will mature over 5 years and have an interest-only period of 30 months at an average rate of 8.75%.\u00a0Subject to certain limitations, Pontifax and Kreos can elect to convert up to half of their outstanding loan into shares of Opiant\u2019s common stock at a conversion price of $19.64 per share. Further information with respect to the Agreement is set forth in a Form 8-K filed by Opiant with the Securities and Exchange Commission on\u00a0December 10, 2020.<\/p>\n

\u201cThis financing, together with the $31.1 million of cash on our balance sheet, provides Opiant with the financial flexibility to potentially launch OPNT003 without the need for additional financing,\u201d said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. \u201cThis Agreement, along with the recent appointment of Craig Collard, a seasoned biopharma leader, as Chairman of our Board of Directors, positions us well to deliver on our mission to develop and bring to market best-in-class medicines for addiction and overdose.\u201d<\/p>\n

\u201cWe look forward to partnering with a company as innovative as Opiant,\u201d said Momi Karako, partner at Pontifax. \u201cThe Company is making excellent progress advancing OPNT003, and it is a privilege to be working with a team whose potential to make a difference is so great.\u201d<\/p>\n

\u201cKreos is pleased to provide this financing to Opiant,\u201d said Aris Constantinides, partner at Kreos Capital. \u201cThis is an underserved market and Opiant, a company advancing the field of addiction,\u00a0could play an important\u00a0role in addressing the growing opioid addiction\u00a0crisis.\u201d<\/p>\n

Jefferies acted as the exclusive financial adviser to Opiant and Wilson, Sonsini, Goodrich & Rosati served as legal advisor. Kramer Levin acted as legal advisor to Pontifax and Kreos Capital.<\/p>\n

\n About\u00a0Opiant Pharmaceuticals, Inc.\u00a0<\/strong>
\n
Opiant Pharmaceuticals, Inc., the company that developed NARCAN\u00ae Nasal Spray, is building a leading\u00a0franchise\u00a0of new medicines to combat addictions and drug overdose.<\/p>\n

For more information visit:\u00a0www.opiant.com<\/a>.<\/p>\n

\n
\n Forward-Looking Statements<\/em>
\n <\/strong>
\n
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended\u00a0December 31, 2019, filed with the\u00a0Securities and Exchange Commission\u00a0on\u00a0March 4, 2020, including under the caption titled “Risk Factors.” \u00a0These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.<\/p>\n

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (\u201cAgreement\u201d) with a syndicate of Pontifax Medison Finance (\u201cPontifax\u201d), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe\u2019s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (\u201cFDA\u201d) at the end of 2021. Under the Agreement, Opiant will be able to draw up to $50 … <\/p>\n

Continue reading “Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOpiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (\u201cAgreement\u201d) with a syndicate of Pontifax Medison Finance (\u201cPontifax\u201d), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe\u2019s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (\u201cFDA\u201d) at the end of 2021. Under the Agreement, Opiant will be able to draw up to $50 … Continue reading "Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T21:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing\",\"datePublished\":\"2020-12-10T21:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/\"},\"wordCount\":750,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/\",\"name\":\"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=\",\"datePublished\":\"2020-12-10T21:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/","og_locale":"en_US","og_type":"article","og_title":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk","og_description":"SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (\u201cAgreement\u201d) with a syndicate of Pontifax Medison Finance (\u201cPontifax\u201d), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe\u2019s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (\u201cFDA\u201d) at the end of 2021. Under the Agreement, Opiant will be able to draw up to $50 … Continue reading \"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T21:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing","datePublished":"2020-12-10T21:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/"},"wordCount":750,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/","name":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=","datePublished":"2020-12-10T21:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDQxMCMzODY2NDg1IzIwMjAwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-secures-50-million-in-convertible-debt-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}